niacinamide has been researched along with Prostatic Neoplasms, Castration-Resistant in 5 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Prostatic Neoplasms, Castration-Resistant: Tumors or cancer of the PROSTATE which can grow in the presence of low or residual amount of androgen hormones such as TESTOSTERONE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sorafenib promotes apoptosis through downstream pathways that can be deregulated in CRPC." | 2.79 | Role of sorafenib in overcoming resistance of chemotherapy-failure castration-resistant prostate cancer. ( Bitran, JD; Cygan, P; Galvez, AG; Lestingi, TM; Meyer, A; Nabhan, C; Tolzien, K, 2014) |
| " In addtion, to improve their bioavailability and reduce their metabolism, we encapsulated sorafenib and nilotinib into styrene-co-maleic acid micelles." | 1.43 | A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer. ( Archibald, M; Greish, K; Nehoff, H; Pritchard, T; Rosengren, RJ; Taurin, S, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Meyer, A | 1 |
| Cygan, P | 1 |
| Tolzien, K | 1 |
| Galvez, AG | 1 |
| Bitran, JD | 1 |
| Lestingi, TM | 1 |
| Nabhan, C | 1 |
| Archibald, M | 1 |
| Pritchard, T | 1 |
| Nehoff, H | 1 |
| Rosengren, RJ | 1 |
| Greish, K | 1 |
| Taurin, S | 1 |
| Wu, H | 1 |
| Zhang, L | 1 |
| Gao, X | 1 |
| Zhang, X | 1 |
| Duan, J | 1 |
| You, L | 1 |
| Cheng, Y | 1 |
| Bian, J | 1 |
| Zhu, Q | 1 |
| Yang, Y | 1 |
| Jeong, CW | 1 |
| Yoon, CY | 1 |
| Jeong, SJ | 1 |
| Hong, SK | 1 |
| Byun, SS | 1 |
| Kwak, C | 1 |
| Lee, SE | 1 |
| Zengerling, F | 1 |
| Streicher, W | 1 |
| Schrader, AJ | 1 |
| Schrader, M | 1 |
| Nitzsche, B | 1 |
| Cronauer, MV | 1 |
| Höpfner, M | 1 |
1 trial available for niacinamide and Prostatic Neoplasms, Castration-Resistant
| Article | Year |
|---|---|
Role of sorafenib in overcoming resistance of chemotherapy-failure castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, | 2014 |
4 other studies available for niacinamide and Prostatic Neoplasms, Castration-Resistant
| Article | Year |
|---|---|
A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Adhesion; Cell Cy | 2016 |
Combination of sorafenib and enzalutamide as a potential new approach for the treatment of castration-resistant prostate cancer.
Topics: Androgen Antagonists; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides | 2017 |
The role of hypoxia-inducible factor-1α and -2α in androgen insensitive prostate cancer cells.
Topics: Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Blotting, Western; Cell Line, T | 2013 |
Effects of sorafenib on C-terminally truncated androgen receptor variants in human prostate cancer cells.
Topics: Androgens; Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Cell Proliferation; Gene Expressi | 2012 |